A Rapid Pharmacogenomic Assay to Detect NAT2 Polymorphisms and Guide Isoniazid Dosing for Tuberculosis Treatment-Reference-Cited by-同舟云学术

A Rapid Pharmacogenomic Assay to Detect NAT2 Polymorphisms and Guide Isoniazid Dosing for Tuberculosis Treatment

Published:2021-12-01 Issue:11 Volume:204 Page:1317-1326
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

Verma Renu¹,Patil Sunita¹,Zhang Nan²,Moreira Flora M. F.³,Vitorio Marize T.³,Santos Andrea da S.³,Wallace Ellen⁴,Gnanashanmugam Devasena⁴,Persing David H.⁴,Savic Rada M.²,Croda Julio⁵⁶,Andrews Jason R.¹^ORCID

Affiliation:

1. Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, California;

2. Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California;

3. Federal University of Grande Dourados, Dourados, Brazil;

4. Cepheid, Sunnyvale, California;

5. School of Medicine, Federal University of Mato Grosso do Sul, Campo Grande, Brazil; and

6. Oswaldo Cruz Foundation Mato Grosso do Sul, Mato Grosso do Sul, Brazil

Publisher

American Thoracic Society

Subject

Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Reference53 articles.

1. Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis

2. A Four-Month Gatifloxacin-Containing Regimen for Treating Tuberculosis

3. High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis

4. Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes

5. Interethnic and Intraethnic Variability of NAT2 Single Nucleotide Polymorphisms

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnosis, prevention and risk-management of drug-induced liver injury due to medications used to treat mycobacterium tuberculosis;Expert Opinion on Drug Safety;2024-09-04

2. Genetic ancestry proportion influences risk of adverse events from tuberculosis treatment in Brazil;2024-08-30

3. A Nanopore Sequencing-based Pharmacogenomic Panel to Personalize Tuberculosis Drug Dosing;American Journal of Respiratory and Critical Care Medicine;2024-06-15

4. Prediction Models for Adverse Drug Reactions During Tuberculosis Treatment in Brazil;The Journal of Infectious Diseases;2024-01-23

5. Risk adjustment model for tuberculosis compared to non-tuberculosis mycobacterium or latent tuberculosis infection: Center for Personalized Precision Medicine of Tuberculosis (cPMTb) cohort database;BMC Pulmonary Medicine;2023-11-24